bortezomib

Related by string. Bortezomib * * bortezomib boron . Velcade bortezomib . bortezomib Velcade R . bortezomib Velcade . bortezomib Velcade ® . R bortezomib . ® bortezomib . R Bortezomib . bortezomib refractory . proteasome inhibitor bortezomib *

Related by context. All words. (Click for frequent words.) 75 gemcitabine 75 trastuzumab 74 docetaxel 74 rituximab 73 erlotinib 73 sorafenib 73 imatinib 72 bevacizumab 72 dasatinib 71 cisplatin 71 gefitinib 71 sunitinib 70 topotecan 70 FOLFIRI 70 FOLFOX 70 cetuximab 70 chlorambucil 70 pemetrexed 70 docetaxel chemotherapy 70 mitoxantrone 70 temsirolimus 70 decitabine 70 doxorubicin 69 FOLFOX4 69 pomalidomide 69 mapatumumab 68 carboplatin 68 irinotecan 68 dacarbazine 68 zoledronic acid 68 azacitidine 68 pegylated liposomal doxorubicin 68 Fludara 68 monotherapy 68 metastatic RCC 68 carboplatin paclitaxel 68 mycophenolate mofetil 68 pertuzumab 68 raltegravir 68 imetelstat 68 chemotherapy regimens 68 temozolomide 67 5 FU 67 bendamustine 67 peginterferon 67 vinorelbine 67 APTIVUS r 67 vandetanib 67 heavily pretreated patients 67 antitumor activity 67 fluorouracil 67 TACE 67 lamivudine 67 taxanes 67 HER2 positive metastatic breast 67 chemotherapeutic agents 67 chemoradiation 66 5FU 66 chemotherapy docetaxel 66 nab paclitaxel 66 NRTIs 66 tocilizumab 66 anti leukemic 66 sorafenib Nexavar 66 neoadjuvant chemotherapy 66 Taxotere ® 66 lapatinib 66 metastatic renal cell carcinoma 66 erlotinib Tarceva ® 66 low dose cytarabine 66 oblimersen 66 chronic lymphocytic leukemia CLL 66 HGS ETR1 66 infliximab 66 azathioprine 66 Bortezomib 66 tipranavir 66 GRN#L 65 etoposide 65 capecitabine 65 tyrosine kinase inhibitors 65 PXD# 65 anti TNF 65 daunorubicin 65 fulvestrant 65 Doxil ® 65 cytarabine 65 idarubicin 65 cilengitide 65 fludarabine 65 PegIFN RBV 65 paclitaxel 65 milatuzumab 65 IFN alpha 65 iniparib 65 methotrexate 65 plus dexamethasone 65 5 fluorouracil 65 5-FU/LV 65 cytotoxic 65 bevacizumab Avastin ® 65 tanespimycin 65 protease inhibitor 65 trabectedin 65 entecavir 65 nilotinib 65 XELOX 65 Targretin 65 chemotherapies 65 cytotoxic chemotherapy 65 DMARDs 65 Taxotere 64 erlotinib Tarceva 64 axitinib 64 paclitaxel Taxol 64 YONDELIS 64 gemcitabine carboplatin 64 Doxil 64 antiviral activity 64 low dose dexamethasone 64 sorafenib Nexavar ® 64 PREZISTA r 64 ixabepilone 64 standard chemotherapy regimens 64 abiraterone acetate 64 tyrosine kinase inhibitor 64 gemcitabine Gemzar 64 adjuvant therapy 64 enfuvirtide 64 posaconazole 64 docetaxel Taxotere 64 adalimumab 64 allopurinol 64 ganetespib 64 imatinib Gleevec 64 telaprevir dosed 64 chemotherapeutic agent 64 CANCIDAS 64 LY# [003] 64 anthracycline 64 imatinib resistant 64 Peg IFN 64 interferon alfa 2a 64 MGCD# [001] 64 gemcitabine cisplatin 64 dacetuzumab 64 seliciclib 64 fondaparinux 64 interferon alfa 64 Trastuzumab 64 chemoradiotherapy 64 elotuzumab 64 bortezomib Velcade R 64 Xcytrin 64 bevacizumab Avastin 64 refractory AML 63 galiximab 63 bicalutamide 63 AEGR 63 Pegasys ® 63 fluconazole 63 mRCC 63 sunitinib malate 63 xenograft models 63 abatacept 63 DFMO 63 lenalidomide Revlimid R 63 perifosine 63 dexamethasone 63 IFN α 63 IMGN# 63 mitomycin 63 HGS# 63 peg IFN 63 mg kg dose 63 standard chemotherapy regimen 63 etanercept 63 cyclophosphamide 63 panitumumab 63 free survival PFS 63 adefovir 63 tumor shrinkage 63 idraparinux 63 Irinotecan 63 epirubicin 63 calcitriol 63 talabostat 63 viral kinetics 63 immunomodulator 63 darunavir ritonavir 63 bleomycin 63 interferon 63 zalutumumab 63 taxane 63 CIMZIA TM 63 EGFR inhibitors 63 NNRTIs 63 TNF inhibitor 63 pegylated interferon 63 adecatumumab 63 nelfinavir 63 vorinostat 63 imatinib therapy 63 exemestane 63 Cytoxan 63 DOXIL 63 insulin glargine 63 IMC A# 63 gefitinib Iressa 63 G CSF 63 liver metastases 63 leucovorin 63 cabazitaxel 63 phenoxodiol 63 trastuzumab Herceptin R 63 Erlotinib 63 recurrent GBM 63 NSCLC 63 plus ribavirin 63 dose cytarabine 63 OXi# 63 ritonavir boosted 63 T#I [002] 63 paclitaxel cisplatin 63 arsenic trioxide 63 nucleoside analogues 63 pazopanib 63 heavily pretreated 63 enzastaurin 63 complete remissions 63 Velcade 62 DMARD 62 advanced NSCLC 62 Pemetrexed 62 SCH # 62 mTOR inhibitors 62 evaluable patients 62 allogeneic SCT 62 mCRC patients 62 OncoVEX GM CSF 62 Gemcitabine 62 Genasense 62 melphalan prednisone 62 nitazoxanide 62 cytotoxicity 62 DAPT 62 obatoclax 62 glufosfamide 62 estramustine 62 lenalidomide 62 FOLPI 62 mcg kg 62 ipilimumab 62 plus prednisone 62 HGS ETR2 62 PLX# 62 sapacitabine 62 Folfox 62 brain metastases 62 pegylated interferon alfa 2b 62 Imprime PGG 62 darunavir 62 MGd 62 oxaliplatin 62 follicular lymphoma 62 gemcitabine chemotherapy 62 temozolomide TMZ 62 protease inhibitor PI 62 celgosivir 62 lopinavir r 62 FOLFOX6 62 EGFr 62 CHOP chemotherapy 62 clodronate 62 TORISEL 62 follicular NHL 62 visilizumab 62 fluoropyrimidine 62 ribavirin 62 amrubicin 62 T DM1 62 trastuzumab Herceptin 62 ceftriaxone 62 vicriviroc 62 neurologic progression 62 Cisplatin 62 CD# antibody [001] 62 ABVD 62 AMN# [001] 62 immunomodulatory 62 chemotherapy regimen 62 cetuximab Erbitux R 62 fibrinolytic 62 metformin 62 5 Fluorouracil 62 TMC# [001] 62 VELCADE melphalan 62 Herceptin trastuzumab 61 paclitaxel Taxol ® 61 CIMZIA ™ 61 carfilzomib 61 virologic failure 61 alkylating agent 61 GVAX 61 INGN 61 custirsen 61 cisplatin chemotherapy 61 cyclophosphamide methotrexate 61 teriflunomide 61 chemotherapeutic regimens 61 refractory multiple myeloma 61 peginterferon alfa 2b 61 Capecitabine 61 lapatinib Tykerb 61 dasatinib Sprycel ® 61 pegylated interferon alfa 2a 61 INCB# [001] 61 bortezomib Velcade 61 abiraterone 61 Gefitinib 61 mTOR inhibitor 61 postoperative chemotherapy 61 picoplatin 61 Bezielle 61 Seliciclib 61 chemotherapeutic drug 61 adjuvant chemotherapy 61 sunitinib Sutent ® 61 placebo dexamethasone 61 anthracycline taxane 61 BMS # 61 peginterferon alfa 2a 61 CA4P 61 octreotide LAR 61 valsartan 61 PREZISTA rtv 61 aromatase inhibitor 61 leukemia CLL 61 S/GSK# 61 cobicistat 61 cediranib 61 neoadjuvant 61 IGF 1R 61 valopicitabine 61 NRTI 61 integrase inhibitor 61 relapsed ovarian cancer 61 metastatic castration resistant 61 aflibercept 61 PEG Interferon lambda 61 Tarceva TM 61 nucleoside 61 relapsed refractory 61 pegylated interferon alpha 61 pioglitazone 61 thalidomide Thalomid 61 solid tumors 61 olaparib 61 dacarbazine chemotherapy 61 disease progression 61 boosted protease inhibitor 61 panobinostat 61 SUTENT 61 mg BID 61 vancomycin 61 Rituximab 61 anastrozole 61 Flu Cy 61 lintuzumab 61 Vectibix 61 adriamycin 61 Velcade bortezomib 61 chemotherapy gemcitabine 61 liposomal doxorubicin 61 Dasatinib 61 docetaxel Taxotere R 61 neratinib 61 HuLuc# 61 anthracyclines 61 CYT# 61 Telintra 61 letrozole 61 relapsed SCLC 61 relapsed multiple myeloma 61 unfractionated heparin 61 EGFR tyrosine kinase inhibitors 61 EGFR mutations 61 interferon therapy 61 ELOXATIN 61 NNRTI 61 dexamethasone Decadron 61 lung metastases 61 linezolid 61 Amrubicin 61 celecoxib 61 oral Xeloda 61 metastatic CRC 61 cetuximab Erbitux ® 61 EpCAM 61 dose dexamethasone 61 AP# [003] 60 Tarceva 60 uric acid lowering 60 Platinol 60 VELCADE 60 natalizumab 60 tiotropium 60 Tamibarotene 60 irinotecan chemotherapy 60 metastatic colorectal cancer 60 Zolinza 60 relapsed MM 60 Xanafide 60 imipenem 60 overlapping toxicities 60 KRAS status 60 BRAF inhibitor 60 VAPRISOL 60 imatinib Gleevec ® 60 abacavir lamivudine 60 irbesartan 60 kinase inhibitor 60 Symadex 60 BAY #-# 60 neoadjuvant therapy 60 Taxotere R 60 tesmilifene 60 panitumumab Vectibix 60 Torisel 60 KRAS wild 60 tamoxifen 60 Lapatinib 60 evaluating tivozanib 60 TNFerade 60 amphotericin B 60 virologic response 60 MDV# 60 trans retinoic acid ATRA 60 lenalidomide dexamethasone 60 aprepitant 60 chemotherapeutics 60 depsipeptide 60 TKIs 60 anticancer agents 60 antitumor effect 60 mCRC 60 rNAPc2 60 Lupuzor ™ 60 leukemia AML 60 TNF inhibitors 60 Traficet EN 60 microtubule targeting 60 castration resistant prostate cancer 60 adalimumab Humira 60 entinostat 60 proteasome inhibitors 60 relapsed refractory multiple myeloma 60 alvespimycin 60 Copegus ribavirin 60 clopidogrel 60 melphalan 60 comparator PI r 60 CsA 60 Taxol 60 PSMA ADC 60 CoFactor 60 mcg albinterferon alfa 2b 60 Actilon 60 ofatumumab 60 dosing regimens 60 infusional 5-FU/LV 60 KRAS mutations 60 K ras mutations 60 TELCYTA 60 Gemzar ® 60 Navelbine 60 itraconazole 60 glucose lowering 60 resistant ovarian cancer 60 dose cohorts 60 goserelin 60 lopinavir 60 interferon ribavirin 60 intravenous bisphosphonates 60 anti VEGF 60 glatiramer acetate 60 cardiac toxicity 60 administered subcutaneously 60 molecularly targeted 60 capecitabine Xeloda 60 anakinra 60 Panzem R NCD 60 CLL 60 alpha 2a 60 bosutinib 60 EGF receptor 60 KRAS mutant tumors 60 Hycamtin 60 ribavirin RBV 60 dasatinib Sprycel 60 elesclomol 60 azacytidine 60 VEGF inhibitors 60 INTELENCE 60 afatinib 60 ponatinib 60 CLL cells 60 protease inhibitors 60 genotypic resistance 60 trans retinoic acid 60 FTY# 60 eribulin 60 relapsed CLL 60 recurrent glioblastoma multiforme 60 plus gemcitabine 60 lesinurad 60 romidepsin 60 Tarvacin 60 antiangiogenic 60 imatinib mesylate 60 nucleoside analogue 60 Xelox 60 Pertuzumab 60 doxorubicin docetaxel 60 pancreatic adenocarcinoma 60 KRAS mutations occur 59 eribulin mesylate 59 olmesartan 59 APTIVUS 59 platinum refractory 59 febuxostat 59 achieve sustained virologic 59 Omacetaxine 59 dosage regimens 59 sitagliptin 59 TAXOTERE R 59 apremilast 59 tamsulosin 59 flavopiridol 59 partial remissions 59 5 FU leucovorin 59 squamous histology 59 Bevacizumab 59 ZD# [001] 59 sustained virologic response 59 docetaxel Taxotere ® 59 neoadjuvant treatment 59 mg/m2 dose 59 ramipril 59 tumor regression 59 interferon alfa 2b 59 veltuzumab 59 Elotuzumab 59 antihypertensive agents 59 Telcyta 59 Gleevec resistant 59 BCR ABL 59 rituximab Rituxan 59 EGFR antibodies 59 CBLC# 59 lumiliximab 59 HBeAg negative patients 59 AZT zidovudine Retrovir 59 surrogate endpoint 59 PSN# [002] 59 dacarbazine DTIC 59 Interferon alfa 59 docetaxel prednisone 59 dose escalation 59 pramlintide 59 caspofungin 59 dosing schedules 59 HuMax CD# 59 nucleoside reverse transcriptase inhibitor 59 HCV 59 forodesine 59 interferon alpha 59 FluCAM 59 alfa 2a 59 investigational protease inhibitor 59 EGFR 59 chemotherapeutic drugs 59 HDACi 59 Rituxan 59 severe neutropenia 59 tolerability profile 59 desvenlafaxine succinate 59 CYC# 59 TNF antagonists 59 hormonal therapy 59 antiangiogenic therapy 59 disease modifying antirheumatic 59 paclitaxel carboplatin 59 doxorubicin cyclophosphamide 59 XmAb# 59 FOLFOX chemotherapy 59 refractory CLL 59 voreloxin 59 radiation sensitizer 59 ritonavir 59 CR# vcMMAE 59 oral rivaroxaban 59 hematological cancers 59 pegylated interferons 59 HDAC inhibitors 59 NATRECOR R 59 APOPTONE 59 PI3K inhibitor 59 LMWH 59 Ceplene/IL-2 59 pan HDAC inhibitor 59 ZOLINZA 59 azoles 59 Aptivus ® 59 favorable pharmacokinetic profile 59 EGFR TKI 59 splenectomized patients 59 biologic therapy 59 N acetylcysteine 59 sorafenib tablets 59 elvitegravir 59 NXL# 59 trastuzumab Herceptin ® 59 mcg dose 59 polymerase inhibitor 59 patients evaluable 59 antidiabetic 59 myeloma cells 59 febrile neutropenia 59 tumor recurrence 59 multiple myeloma 59 VIDAZA 59 rivaroxaban 59 tamoxifen therapy 59 cisplatin gemcitabine 59 Cetuximab 59 kinase inhibitors 59 HuMax EGFr 59 Imatinib 59 limiting toxicity 59 iodixanol 59 active comparator 59 comparator arm 59 ASA# 59 PEG SN# 59 PEGPH# 59 EFAPROXYN 59 cytarabine daunorubicin 59 EGFR TKIs 59 daclizumab 59 Sym# 59 Tarceva erlotinib 59 bevacizumab Avastin R 59 indolent NHL 59 MabCampath 59 metastatic disease 59 Vandetanib 59 Cremophor 59 antitumor 59 cetuximab Erbitux 59 insulin sensitizing 59 letrozole Femara 59 bosentan 59 relapsing remitting multiple sclerosis 59 HCV genotypes 59 bone metastasis 59 angiogenesis inhibitor 59 Perifosine 59 CTLA 4 59 elacytarabine 59 immunosuppressive agents 59 metastatic melanoma 59 GnRH agonists 59 belatacept 59 pegylated interferon alfa 59 anti angiogenic 59 preoperative chemotherapy 59 ISENTRESS 59 GM CSF 59 AEG# 59 Taxotere chemotherapy 59 chemotherapeutic regimen 59 Vectibix monotherapy 59 motesanib 59 CCR2 59 abciximab 59 intravenously administered 59 bortezomib Velcade ® 59 pro apoptotic 58 PegIFN 58 belimumab 58 receptor tyrosine kinase inhibitor 58 superficial bladder cancer 58 Amigal 58 VFEND 58 Allovectin 7 ® 58 proteasome inhibitor 58 TNF α 58 capecitabine Xeloda R 58 methotrexate MTX 58 interferons 58 mitoxantrone chemotherapy 58 chemotherapy 58 levosimendan 58 administered orally 58 Peginterferon 58 potent antiviral 58 montelukast 58 4mg/kg 58 recurrent NSCLC 58 glargine 58 Preclinical studies 58 ceftaroline 58 atrasentan 58 Ontak 58 PRT# 58 tenofovir emtricitabine 58 Gleevec 58 Xeloda 58 refractory NSCLC 58 immunosuppressant 58 Cloretazine 58 DMARDS 58 Aflibercept 58 chemotherapy FOLFOX 58 ELACYT 58 Tavocept 58 #mg/m# [001] 58 doxorubicin HCl liposome injection 58 tigecycline 58 bone metastases 58 dose limiting toxicities 58 insulin detemir 58 romiplostim 58 vidofludimus 58 imiquimod 58 median PFS 58 pemetrexed Alimta 58 Alkeran 58 T#I mutation 58 locoregional 58 TREANDA 58 mg/m2 58 cidofovir 58 palifosfamide 58 biochemical relapse 58 oral antiviral 58 LEVADEX 58 unresectable 58 sirolimus 58 preclinical studies 58 SCCHN 58 RG# [001] 58 ACTEMRA TM 58 ovarian carcinoma 58 #mg/m# [002] 58 ISTODAX 58 Carfilzomib 58 HCV SPRINT 58 carvedilol 58 TRIOLEX 58 EndoTAGTM 1 58 achieved ACR# 58 daptomycin 58 paclitaxel chemotherapy 58 moxifloxacin 58 regorafenib 58 interferon beta 58 TYKERB 58 LY# [002] 58 eniluracil 58 Halaven 58 Sorafenib 58 tolvaptan 58 glioblastoma 58 oral allopurinol 58 metastatic hormone refractory 58 Interferon alpha 58 sipuleucel T 58 lupus nephritis 58 therapeutic regimens 58 liposomal formulation 58 antithrombotic 58 cyclophosphamide Cytoxan 58 brentuximab vedotin 58 Kaplan Meier analysis 58 Hsp# inhibitors 58 HRPC 58 Neulasta ® 58 telaprevir 58 virologic 58 CMV disease 58 crizotinib PF # 58 doripenem 58 Fludarabine 58 bivalirudin 58 HBeAg positive 58 HER2 positive breast cancer 58 eplerenone 58 Vidofludimus 58 metastatic breast cancer 58 concurrent chemoradiation 58 PARP inhibitor 58 gastrointestinal stromal tumors GIST 58 pamidronate 58 Valortim R 58 adjuvant radiation 58 sorafenib Nexavar R 58 weekly subcutaneous injections 58 ON #.Na 58 alpha interferon 58 stavudine d4T 58 PARP inhibitors 58 tipifarnib 58 alteplase 58 Taxol ® 58 endocrine therapy 58 differentiated thyroid 58 allogeneic stem cell 58 3TC lamivudine Epivir 58 anti EGFR antibody 58 pyrazinamide 58 tenofovir Viread 58 LEXIVA r 58 iniparib BSI 58 histone deacetylase HDAC inhibitor 58 efalizumab 58 ACTEMRA 58 FOLFIRINOX 58 tolerability 58 fluvastatin 58 ATACAND 58 humanized anti 58 achieved statistical significance 58 ENMD # 58 secondary efficacy endpoints 58 gamma secretase inhibitor 58 HAART regimens 58 pCR 58 pralatrexate 58 pyridostigmine 58 Omnitarg 58 GPIIb IIIa 58 inhibitor RG# 58 receiving VICTRELIS 58 rituximab Rituxan ® 58 Jevtana 58 voriconazole 58 sustained virological response 58 chronic myeloid leukemia CML 58 Revlimid 58 TNFα 58 anticancer 58 Pegasys plus Copegus 58 receptor inhibitor 58 hypomethylating agents 58 targeting CD# 58 pharmacodynamic properties 58 HCV genotype 1 58 IFN beta 58 Azedra 58 Campath alemtuzumab 58 preclinically 58 EBRT 58 oral prodrug 58 pharmacodynamic 58 belinostat 58 Combination therapy 58 dexrazoxane 58 cisplatin vinorelbine 58 interferon IFN 58 HBeAg negative 58 FLT3 58 cytotoxic agents 58 Elvitegravir 58 sulfasalazine 58 Vidaza 58 cyclophosphamide chemotherapy 58 intermittent dosing 58 JAK2 inhibitors 58 HSCT 58 peg interferon 58 prostate cancer CRPC 58 fluticasone salmeterol 57 iclaprim 57 T#I mutant 57 pegylated 57 chemotherapeutic 57 methotrexate monotherapy 57 MAGE A3 ASCI 57 remission induction 57 #D#C# 57 ACZ# 57 Fulvestrant 57 mg dose 57 calcineurin inhibitors 57 BRAF mutation 57 taxol 57 randomized Phase III 57 amprenavir 57 protein kinase inhibitor 57 pegfilgrastim 57 nucleoside analog 57 distant metastasis 57 rindopepimut 57 HER2 negative 57 nonresponders 57 histologies 57 noninferiority 57 RDEA# 57 taxane therapy 57 taxane chemotherapy 57 HCV RESPOND 2 57 LEXIVA 57 Marqibo 57 randomized multicenter Phase III 57 subcutaneously administered 57 evaluable 57 satraplatin 57 EZN 57 thymalfasin 57 seropositive patients 57 induce apoptosis 57 ocrelizumab 57 GVHD 57 MDM2 57 Sutent 57 CR nPR 57 ddI 57 HCV protease 57 risedronate 57 phase IIb clinical 57 fenofibric acid 57 flutamide 57 Pegylated Interferon 57 VEGFR2 57 IGF 1R inhibitor 57 EOquin TM 57 iNOS 57 Dapagliflozin 57 Roche Pegasys 57 rizatriptan 57 Elitek 57 metastatic colon cancer 57 ribavirin therapy 57 rapamycin 57 bevirimat 57 colorectal liver metastases 57 multi kinase inhibitor 57 mg/m2/day 57 AQ4N 57 atacicept 57 FOLFIRI alone 57 low dose ritonavir 57 GnRH agonist 57 viral kinetic 57 BEACOPP 57 gemcitabine Gemzar ® 57 CDK inhibitor 57 metastatic HRPC 57 demonstrated antitumor activity 57 Revlimid lenalidomide 57 CCR5 antagonist 57 amoxicillin clavulanate 57 forskolin 57 vinca alkaloid 57 paricalcitol 57 complete cytogenetic response 57 rHuPH# 57 isoproterenol 57 anti angiogenic agents 57 HBeAg seroconversion 57 xanthine oxidase inhibitor 57 erythropoietic 57 pharmacodynamic profile 57 fosamprenavir 57 Lenalidomide 57 DLBCL 57 antipsychotic 57 Pharmacokinetics PK 57 maraviroc 57 prostate cancer mCRPC 57 basal insulin 57 PKC# 57 nucleoside reverse transcriptase inhibitors 57 cell lymphoma CTCL 57 anticancer therapies 57 distant metastases 57 atazanavir 57 temsirolimus Torisel ® 57 eculizumab 57 chemoresistance 57 Blinatumomab 57 HDAC 57 deforolimus 57 progression TTP 57 anti TNF alpha 57 Phase Ib II 57 piperacillin tazobactam

Back to home page